- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innocare Pharma Ltd (9969)
Innocare Pharma Ltd stock price live, this page displays HK 9969 stock exchange data. View the 9969 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Innocare Pharma Ltd real time stock price chart below.
What Is the Innocare Pharma Ltd Stock Price Today?
The Innocare Pharma Ltd stock price today is 12.60.
What Is the Stock Symbol for Innocare Pharma Ltd?
The stock symbol for Innocare Pharma Ltd is "9969."
What Stock Exchange Does Innocare Pharma Ltd Trade On?
Innocare Pharma Ltd is listed and trades on the Hong Kong stock exchange.
Is Innocare Pharma Ltd a Good Stock to Buy?
Determining whether Innocare Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9969 quote. (ISIN: KYG4783B1032)
What Is the Innocare Pharma Ltd Stock Price Today?
The Innocare Pharma Ltd stock price today is 12.60.
What Is the Stock Symbol for Innocare Pharma Ltd?
The stock symbol for Innocare Pharma Ltd is "9969."
What Stock Exchange Does Innocare Pharma Ltd Trade On?
Innocare Pharma Ltd is listed and trades on the Hong Kong stock exchange.
Is Innocare Pharma Ltd a Good Stock to Buy?
Determining whether Innocare Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9969 quote. (ISIN: KYG4783B1032)
12.60
-0.13(-1.02%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.48
12.79
52 wk Range
5.69
20.62
9969 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.4812.79
52 wk Range
5.6920.62
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
9969 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
19.67
Upside
+56.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Innocare Pharma Ltd Company Profile
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a registrational trial for the treatment of solid tumor patients, including cholangiocarcinoma; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase II clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, the company develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, the company offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Compare 9969 to Peers and Sector
Metrics to compare | 9969 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9969PeersSector | |
|---|---|---|---|---|
P/E Ratio | −97.6x | −14.8x | −0.5x | |
PEG Ratio | −2.79 | 0.04 | 0.00 | |
Price/Book | 3.4x | 5.1x | 2.6x | |
Price / LTM Sales | 15.7x | 14.2x | 3.3x | |
Upside (Analyst Target) | 57.4% | 50.2% | 45.5% | |
Fair Value Upside | Unlock | −2.0% | 5.1% | Unlock |
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 19.67
(+56.09% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
383.89M / --
FAQ
What Is the Innocare (9969) Stock Price Today?
The Innocare stock price today is 12.60
What Stock Exchange Does Innocare Trade On?
Innocare is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Innocare?
The stock symbol for Innocare is "9969."
What Is the Innocare Market Cap?
As of today, Innocare market cap is 25.39B.
What Is Innocare's Earnings Per Share (TTM)?
The Innocare EPS (TTM) is -0.14.
From a Technical Analysis Perspective, Is 9969 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Innocare Stock Split?
Innocare has split 0 times.
How Many Employees Does Innocare Have?
Innocare has 1176 employees.
What is the current trading status of Innocare (9969)?
As of Feb 13, 2026, Innocare (9969) is trading at a price of 12.60, with a previous close of 12.73. The stock has fluctuated within a day range of 12.48 to 12.79, while its 52-week range spans from 5.69 to 20.62.
What Is Innocare (9969) Price Target According to Analysts?
The average 12-month price target for Innocare is HKD19.67, with a high estimate of HKD27.68289921 and a low estimate of HKD12.46092865. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +56.09% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.